US 11,911,461 B1
Adjuvanted vaccines containing modified S1 Spike protein of SARS-CoV-2 variant C.1.2 for subcutaneous administration and methods of use
David Craig Wright, Pacific Grove, CA (US); Michael Bowe, Marina, CA (US); Emily Wright, Covina, CA (US); and Peter Pushko, Frederick, MD (US)
Assigned to D4 Labs, LLC, Pacific Grove, CA (US)
Filed by D4 Labs, LLC, Pacific Grove, CA (US)
Filed on May 5, 2023, as Appl. No. 18/313,017.
Int. Cl. A61K 39/215 (2006.01); A61K 39/00 (2006.01); A61K 39/42 (2006.01); A61P 31/14 (2006.01); C07K 16/10 (2006.01); A61P 37/04 (2006.01)
CPC A61K 39/215 (2013.01) [A61P 37/04 (2018.01); A61K 2039/545 (2013.01); A61K 2039/55555 (2013.01)] 16 Claims
 
1. An adjuvanted protein vaccine comprising: a SARS-CoV-2 variant C.1.2 modified S1 Spike protein sequence and a non-phospholipid liposome, wherein the protein is encapsulated within the non-phospholipid liposome.